Madam Therapeutics received an award in the NECTAR program
The Dutch funding agency NOW today announced that close to fifty scientists and twenty companies, funds and foundations have been awarded funding from the Dutch government to work on the development of new accessible and affordable antibiotics, and alternatives to antibiotic use.
Madam Therapeutics is part of one of the 8 consortia that have received an award in this NECTAR program. Our project project is entitled next stage development of the novel synthetic antimicrobial peptide SAAP-148 (NESDAP). In this project we will develop chemical modifications to increase our peptide’s ability to penetrate cells. Several strategies, e.g. nanoparticles and PLGA microspheres, to optimize the delivery of SAAP-148 deep into wounds with a controlled release over time will be developed in parallel. Efficacy of combinations of optimal formulations and SAAP-148 will be investigated in animal models for chronic wound infections.